Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Multiple sclerosis – predicting treatment success

07.01.2014
People with multiple sclerosis often have problems with their gait. A drug that can help them is unfortunately only effective in fewer than half of patients. Now medics from the Department of Neurology at the University of Würzburg have developed a method for predicting the success of this treatment.

People who suffer from multiple sclerosis (MS) have centers of inflammation in the brain and spinal cord, which cause symptoms that range in severity depending on their site and size. Many patients have gait problems that seriously impede them in everyday life.

The medicine of choice in this case is the agent fampridine, which has been approved in Germany since 2011. It blocks potassium channels on the surface of nerve axons and, in so doing, can improve the conductivity of nerve fibers. After taking fampridine, many sufferers are able to walk more quickly again; they also report that they feel steadier walking.

However, studies even before the approval of fampridine have shown that fewer than half of patients with MS actually benefit from taking the drug. The rest experience no change in their ability to walk. For this reason, physicians can currently only give the medication to their patients for two weeks initially as a trial. Only if the ability to walk has improved markedly after this time are they permitted to prescribe the drug on a permanent basis.

Magnetic stimulation to predict treatment success

A method for predicting treatment success has now been developed by scientists from the University of Würzburg. The team, led by medics Dr. Daniel Zeller and Dr. Mathias Buttmann, turned to a painless examination technique known as transcranial magnetic stimulation, which works without the use of harmful rays and has been used in clinical routine measurements for many years. The researchers have now published the results of their work in the Journal of Neurology, Neurosurgery and Psychiatry.

“We have taken a closer look at the correlation between the conduction velocity of motor pathways in the central nervous system and the response of gait disturbance to fampridine in patients with MS,” is how Daniel Zeller describes the study. Their findings are unequivocal: “With the help of magnetic stimulation it is possible to say in advance whether fampridine will improve a particular patient’s ability to walk,” says the medic.

The study

Twenty MS patients were examined by the scientists in this study. Prior to treatment with fampridine, they used transcranial magnetic stimulation to determine the so-called central motor conduction time (CMCT). This is the time that an electrical impulse takes to travel from the cerebral cortex to the nerve root level with the spine. “The central motor conduction time primarily reflects the degree of damage to motor pathways as a result of inflammatory demyelinating lesions,” explains Zeller.

The scientists also measured the walking speed of their study participants prior to beginning treatment as well as on day 14 of taking fampridine. Only if the speed increased by at least 20 percent over two different distances did they interpret this as a successful response to treatment.

The findings

The study revealed a significant correlation between the CMCT and the changes in walking speed while taking fampridine: the longer the CMCT was prior to treatment, the better the patients responded to the medication. In addition, the average CMCT prior to treatment in the group of treatment responders was significantly higher than in patients who did not respond to fampridine (the non-responders). The same result was also found when the scientists relaxed the response criterion to include a ten-percent improvement over both walking distances.

In summary, the study demonstrated that taking fampridine brought no improvements in walking speed for any patient with a normal CMCT. All the participants for whom the drug was effective had a longer CMCT prior to starting treatment. And only in some patients with a longer CMCT did fampridine treatment remain unsuccessful.

“This finding is consistent with what we presume is fampridine’s mode of action,” says Daniel Zeller. The agent ultimately improves impulse conduction in central pathways and their conduction velocity.

In particular, however, the study indicated that MS patients with a normal central conduction time are extremely unlikely to benefit from fampridine, whereas a longer CMCT prior to treatment increases the possibility of a response. If these results are confirmed by a larger study, magnetic stimulation could help neurologists in clinical practice to estimate the likely success of treatment with fampridine in advance, thereby avoiding unnecessary fampridine treatment trials.

About Transcranial Magnetic Stimulation

In Transcranial Magnetic Stimulation, physicians place a ring-shaped magnetic coil near the skull. This coil produces a rapidly changing magnetic field that sends magnetic impulses through the skullcap into the brain. There it triggers an action potential in the neurons and the nerve cell transmits an impulse, which in turn can be measured from outside. Even though the technology is only a few decades old, it is now routinely used in research and diagnostics.

Central motor conduction time may predict response to fampridine in multiple sclerosis patients. Daniel Zeller, Karlheinz Reiners, Stefan Bräuninger, Mathias Buttmann. J Neurol Neurosurg Psychiatry doi:10.1136/jnnp-2013-306860.

Contact

Dr. Daniel Zeller, Department of Neurology at the University of Würzburg
T: +49 (0)931 201-23766, e-mail: Zeller_D@ukw.de or
Dr. Mathias Buttmann, Department of Neurology at the University of Würzburg
T.: +49 (0)931 201-24617, e-mail: m.buttmann@ukw.de

Gunnar Bartsch | idw
Further information:
http://www.uni-wuerzburg.de

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>